FibroGen, Inc. (FGEN)
FGEN Stock Price Chart
Explore FibroGen, Inc. interactive price chart. Choose custom timeframes to analyze FGEN price movements and trends.
FGEN Company Profile
Discover essential business fundamentals and corporate details for FibroGen, Inc. (FGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Nov 2014
Employees
225.00
Website
https://www.fibrogen.comCEO
Thane Wettig
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FGEN Financial Timeline
Browse a chronological timeline of FibroGen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$4.01, while revenue estimate is $1.64M.
Earnings released on 11 Aug 2025
EPS came in at -$3.38 falling short of the estimated -$2.25 by -50.22%, while revenue for the quarter reached $1.35M , missing expectations by -53.52%.
Stock split effective on 17 Jun 2025
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2025
EPS came in at -$4.00 falling short of the estimated $0.75 by -633.33%, while revenue for the quarter reached $2.74M , beating expectations by +36.95%.
Earnings released on 17 Mar 2025
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached -$123.26M , missing expectations by -594.81%.
Earnings released on 12 Nov 2024
EPS came in at -$0.17 surpassing the estimated -$0.38 by +55.26%, while revenue for the quarter reached $46.33M , beating expectations by +129.09%.
Earnings released on 6 Aug 2024
EPS came in at -$0.16 surpassing the estimated -$0.26 by +38.46%, while revenue for the quarter reached $50.64M , beating expectations by +46.11%.
Earnings released on 6 May 2024
EPS came in at -$0.33 falling short of the estimated -$0.31 by -6.45%, while revenue for the quarter reached $55.90M , beating expectations by +52.45%.
Earnings released on 26 Feb 2024
EPS came in at -$0.57 falling short of the estimated -$0.42 by -35.71%, while revenue for the quarter reached $27.14M , missing expectations by -30.24%.
Earnings released on 6 Nov 2023
EPS came in at -$0.52 surpassing the estimated -$0.68 by +23.53%, while revenue for the quarter reached $40.13M , beating expectations by +2.15%.
Earnings released on 7 Aug 2023
EPS came in at -$0.65 surpassing the estimated -$0.72 by +9.72%, while revenue for the quarter reached $44.32M , beating expectations by +27.57%.
Earnings released on 8 May 2023
EPS came in at -$0.81 falling short of the estimated -$0.76 by -6.58%, while revenue for the quarter reached $36.16M , beating expectations by +13.57%.
Earnings released on 27 Feb 2023
EPS came in at -$0.70 surpassing the estimated -$0.95 by +26.32%, while revenue for the quarter reached $34.37M , beating expectations by +43.38%.
Earnings released on 7 Nov 2022
EPS came in at -$0.98 falling short of the estimated -$0.83 by -18.07%, while revenue for the quarter reached $15.74M , missing expectations by -50.24%.
Earnings released on 8 Aug 2022
EPS came in at -$0.78 surpassing the estimated -$0.94 by +17.02%, while revenue for the quarter reached $29.81M , missing expectations by -17.57%.
Earnings released on 9 May 2022
EPS came in at -$0.68 surpassing the estimated -$0.84 by +19.05%, while revenue for the quarter reached $60.83M , beating expectations by +111.51%.
Earnings released on 28 Feb 2022
EPS came in at -$1.45 falling short of the estimated -$0.68 by -113.24%, while revenue for the quarter reached $16.54M , missing expectations by -65.28%.
Earnings released on 9 Nov 2021
EPS came in at $0.54 surpassing the estimated $0.01 by +9.10K%, while revenue for the quarter reached $155.97M , beating expectations by +17.34%.
Earnings released on 9 Aug 2021
EPS came in at -$1.45 falling short of the estimated -$0.48 by -202.08%, while revenue for the quarter reached $24.36M , missing expectations by -64.73%.
Earnings released on 10 May 2021
EPS came in at -$0.78 surpassing the estimated -$0.90 by +13.33%, while revenue for the quarter reached $38.43M , missing expectations by -36.72%.
Earnings released on 1 Mar 2021
EPS came in at -$0.64 falling short of the estimated -$0.29 by -120.69%, while revenue for the quarter reached $65.00M , missing expectations by -35.52%.
Earnings released on 5 Nov 2020
EPS came in at $0.35 surpassing the estimated -$0.80 by +143.75%, while revenue for the quarter reached $44.03M , missing expectations by -56.25%.
FGEN Stock Performance
Access detailed FGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.